ICPT - Intercept Pharmaceuticals Inc Stock Price, Fair Value and News

19.00USD Delayed

Market Summary

USD19.00

Delayed

ICPT Stock Price

View Fullscreen

ICPT RSI Chart

ICPT Valuation

Market Cap

794.7M

Price/Earnings (Trailing)

-12.9

Price/Sales (Trailing)

2.5

Price/Free Cashflow

-12.5

ICPT Price/Sales (Trailing)

ICPT Profitability

Operating Margin

99.80%

Return on Equity

-85.76%

Return on Assets

-15.67%

Free Cashflow Yield

-8%

ICPT Fundamentals

ICPT Revenue

Revenue (TTM)

317.7M

Rev. Growth (Yr)

14.44%

Rev. Growth (Qtr)

6.06%

ICPT Earnings

Earnings (TTM)

-61.6M

Earnings Growth (Yr)

-101.04%

Earnings Growth (Qtr)

52.41%

Breaking Down ICPT Revenue

Last 7 days

0.1%

Last 30 days

2.2%

Last 90 days

81.3%

Trailing 12 Months

27.8%

How does ICPT drawdown profile look like?

ICPT Financial Health

Current Ratio

4.22

Debt/Equity

3.12

Debt/Cashflow

-0.28

ICPT Investor Care

Shares Dilution (1Y)

33.79%

Diluted EPS (TTM)

-1.48

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	294.5M	306.5M	317.7M	0
2022	262.6M	266.2M	277.1M	285.7M
2021	297.3M	288.3M	275.4M	260.8M
2020	272.4M	283.4M	300.9M	312.7M
2019	196.1M	218.8M	233.8M	252.0M
2018	145.9M	158.6M	164.2M	179.8M
2017	45.6M	70.9M	107.1M	131.0M
2016	1.8M	6.9M	11.6M	25.0M
2015	2.8M	2.8M	2.8M	2.8M
2014	1.6M	1.7M	1.7M	1.7M
2013	2.1M	1.7M	1.6M	1.6M
2012	2.6M	2.9M	2.8M	2.4M
2011	0	0	0	1.8M

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Intercept Pharmaceuticals Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Nov 08, 2023	miller-rich nancy	back to issuer	-154,109	19.00	-8,111	-
Nov 08, 2023	benatti luca	back to issuer	-154,109	19.00	-8,111	-
Nov 08, 2023	santini gino	back to issuer	-154,109	19.00	-8,111	-
Nov 08, 2023	ford david a	back to issuer	-406,600	19.00	-21,400	chief human resources officer
Nov 08, 2023	miller-rich nancy	sold	-423,776	19.00	-22,304	-
Nov 08, 2023	akkaraju srinivas	sold	-719,853	19.00	-37,887	-
Nov 08, 2023	saik andrew	back to issuer	-859,636	19.00	-45,244	evp & chief financial officer
Nov 08, 2023	venezia rocco	sold	-204,858	19.00	-10,782	chief accounting officer
Nov 08, 2023	akkaraju srinivas	back to issuer	-154,109	19.00	-8,111	-
Nov 08, 2023	venezia rocco	back to issuer	-278,711	19.00	-14,669	chief accounting officer

Which funds bought or sold ICPT recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 22, 2024	MetLife Investment Management, LLC	sold off	-100	-400,464	-	-%
Mar 11, 2024	VANGUARD GROUP INC	sold off	-100	-38,400,600	-	-%
Mar 01, 2024	GOLDMAN SACHS GROUP INC	sold off	-100	-18,893,600	-	-%
Feb 28, 2024	AMERICAN INTERNATIONAL GROUP, INC.	sold off	-100	-375,324	-	-%
Feb 26, 2024	Virtu Financial LLC	sold off	-100	-475,000	-	-%
Feb 20, 2024	Quarry LP	sold off	-100	-116,394	-	-%
Feb 16, 2024	PRICE T ROWE ASSOCIATES INC /MD/	sold off	-100	-490,000	-	-%
Feb 15, 2024	State of Wyoming	sold off	-100	-59,569	-	-%
Feb 15, 2024	JANE STREET GROUP, LLC	sold off	-100	-263,286	-	-%
Feb 15, 2024	Virtus ETF Advisers LLC	sold off	-100	-468,543	-	-%

Are Funds Buying or Selling ICPT?

Are funds buying ICPT calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ICPT

No. of Funds

Unveiling Intercept Pharmaceuticals Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Oct 10, 2023	vanguard group inc	4.95%	2,071,222	SC 13G/A
Jul 10, 2023	vanguard group inc	11.26%	4,693,807	SC 13G/A
Jul 07, 2023	blackrock inc.	10.5%	4,396,970	SC 13G/A
Feb 14, 2023	point72 asset management, l.p.	0.4%	166,300	SC 13G/A
Feb 09, 2023	vanguard group inc	8.78%	3,637,935	SC 13G/A
Feb 02, 2023	state street corp	7.67%	3,175,925	SC 13G/A
Jan 31, 2023	blackrock inc.	7.4%	3,084,833	SC 13G/A
Jan 13, 2023	millennium management llc	2.4%	976,706	SC 13G/A
Oct 12, 2022	point72 asset management, l.p.	4.9%	2,019,983	SC 13G
Oct 11, 2022	fmr llc	-	0	SC 13G/A

Peers (Alternatives to Intercept Pharmaceuticals Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	42.1B	6.8B	3.52%	-17.31%	-8.94	6.15	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.1B	1.8B	-3.68%	-28.69%	-41.18	9.92	76.23%	61.08%
BMRN	15.3B	2.5B	-7.53%	-16.73%	74.64	6.2	13.74%	186.89%
INCY	11.7B	3.8B	-8.64%	-30.91%	15.68	3.1	8.58%	129.81%
MID-CAP
APLS	5.3B	396.6M	-24.84%	-46.72%	-10.08	13.44	425.83%	18.94%
BBIO	4.5B	-	-17.14%	78.66%	-6.9	60.35	54.84%	-34.79%
AXSM	3.5B	270.6M	-7.57%	4.22%	-14.61	12.91	440.80%	-27.84%
ARWR	2.8B	240.7M	-20.91%	-36.67%	-9.44	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-9.63%	-23.17%	-44.93	3.79	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-5.58%	-11.16%	24.84	4.45	85.90%	-14.05%
NVAX	606.0M	983.7M	-9.41%	-43.91%	-1.11	0.62	-50.36%	17.16%
CRBP	388.7M	881.7K	-5.61%	336.79%	-8.71	466.16	-77.61%	-5.33%
INO	267.6M	4.9M	-17.51%	25.55%	-1.98	54.99	-54.97%	51.71%
IBIO	6.0M	2.1M	-57.88%	56.88%	-0.22	2.14	-13.45%	66.37%

Intercept Pharmaceuticals Inc News

Latest updates

Intercept Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Income Statement (Quarterly)																					(In Millions)
Description	(%) Q/Q	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3
Revenue	6.1%	89.00	84.00	68.00	77.00	78.00	72.00	59.00	69.00	67.00	68.00	57.00	83.00	80.00	77.00	73.00	72.00	62.00	66.00	52.00	53.00	47.00
Cost Of Revenue	6.5%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.00	-2.20	2.00	2.00	1.00	2.00	0.00	1.00	1.00	1.00	1.00
Costs and Expenses	2.8%	93.00	91.00	100	95.00	88.00	85.00	86.00	90.00	86.00	82.00	111	44.00	135	129	156	161	137	130	136	135	105
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	136	135	105
S&GA Expenses	-14.8%	45.00	53.00	58.00	55.00	43.00	40.00	38.00	40.00	41.00	44.00	59.00	-2.03	71.00	93.00	99.00	94.00	77.00	70.00	77.00	71.00	57.00
R&D Expenses	11.3%	42.00	37.00	42.00	40.00	44.00	45.00	48.00	50.00	45.00	38.00	51.00	49.00	49.00	34.00	57.00	65.00	60.00	60.00	58.00	63.00	48.00
Interest Expenses	-35.9%	2.00	3.00	3.00	4.00	5.00	5.00	7.00	15.00	14.00	13.00	12.00	12.00	12.00	12.00	12.00	12.00	12.00	10.00	8.00	8.00	8.00
Net Income	52.4%	-2.79	-5.86	-32.13	-20.82	267	-7.53	-17.28	-36.28	-3.63	-11.09	-40.42	-52.15	-66.47	-63.28	-92.98	-98.16	-84.83	-71.42	-90.27	-88.00	-64.45
Net Income Margin	-128.5%	-0.19*	0.68*	0.70*	0.78*	0.74*	-0.24*	-0.26*	-0.35*	-0.39*	-0.59*	-0.75*	-0.88*	-1.07*	-1.20*	-1.28*	-1.37*	-1.43*	-1.44*	-1.62*	-1.72*	-2.02*
Free Cashflow	172.5%	17.00	-23.00	-51.30	-4.51	-16.92	14.00	-20.13	5.00	4.00	5.00	-55.03	-19.71	-41.81	-15.07	-99.16	-60.58	-46.77	-46.24	-84.16	-52.93	-51.58

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3
Assets	-18.9%	393	485	504	554	559	499	503	527	523	523	520	580	591	637	662	755	802	853	438	509	557
Current Assets	-18.5%	383	471	490	540	545	487	477	508	496	493	488	546	561	607	628	721	769	819	403	482	529
Cash Equivalents	-24.6%	103	136	61.00	51.00	113	58.00	48.00	85.00	68.00	146	93.00	58.00	45.00	51.00	41.00	70.00	63.00	94.00	55.00	43.00	59.00
Inventory	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	7.00	7.00	7.00
Net PPE	-9.3%	1.00	1.00	1.00	1.00	1.00	1.00	3.00	3.00	4.00	5.00	5.00	6.00	5.00	4.00	5.00	5.00	6.00	7.00	7.00	10.00	11.00
Liabilities	-23.0%	321	417	437	461	452	868	875	711	679	726	720	747	722	716	697	703	671	678	493	490	461
Current Liabilities	-51.4%	91.00	187	207	230	222	151	151	168	144	145	146	179	163	164	150	162	140	125	108	114	88.00
Long Term Debt	0.1%	224	224	223	223	223	714	717	540	530	576	568	561	553	546	539	532	525	545	375	371	367
LT Debt, Non Current	0.1%	224	224	223	223	223	714	717	540	530	576	568	561	553	546	539	532	525	545	375	371	367
Shareholder's Equity	6.4%	72.00	68.00	67.00	93.00	108	-	-	-	-	-	-	-	-	-	-	52.00	131	175	-	19.00	96.00
Retained Earnings	-0.1%	-2,177	-2,174	-2,169	-2,136	-2,116	-2,383	-2,375	-2,489	-2,453	-2,449	-2,438	-2,398	-2,346	-2,279	-2,216	-2,123	-2,025	-1,940	-1,869	-1,778	-1,690
Additional Paid-In Capital	0.3%	2,257	2,250	2,244	2,238	2,232	2,016	2,008	2,309	2,300	2,249	2,241	2,234	2,218	2,202	2,186	2,176	2,157	2,116	1,815	1,800	1,788
Shares Outstanding	0.1%	42.00	42.00	42.00	42.00	31.00	30.00	30.00	30.00	32.00	33.00	33.00	33.00	33.00	33.00	33.00	32.00	31.00	31.00	30.00	28.00	28.00
Float	-	-	-	-	-	-	335	-	-	-	555	-	-	-	1,259	-	-	-	2,028	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3
Cashflow From Operations	171.6%	16,686	-23,302	-51,597	-4,806	-16,588	14,738	-20,124	5,175	3,562	4,847	-54,650	-17,813	-40,478	-14,842	-98,731	-60,484	-46,756	-45,948	-83,425	-52,812	-51,581
Share Based Compensation	6.2%	6,653	6,262	5,864	5,231	5,788	5,489	5,381	7,151	7,188	5,274	8,419	4,805	15,825	16,083	12,473	13,173	13,130	14,782	14,897	11,499	11,994
Cashflow From Investing	-38.3%	59,774	96,946	59,323	-54,935	331,582	-578	-14,220	15,328	-84,257	48,315	91,340	29,844	35,092	26,064	71,817	65,888	16,475	-365,818	94,467	36,929	31,542
Cashflow From Financing	-255711.6%	-109,999	-43.00	-254	-5,672	-257,402	-3,924	-318	-965	3,390	-224	-1,083	-156	-226	442	-753	5,880	892	450,595	152	440	1,262

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

ICPT Income Statement

2023-09-30

Condensed Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Condensed Consolidated Statements of Operations
Revenue	$ 88,789	$ 77,588	$ 240,465	$ 208,491
Revenue, Product and Service [Extensible Enumeration]	us-gaap:ProductMember	us-gaap:ProductMember	us-gaap:ProductMember	us-gaap:ProductMember
Operating expenses:
Cost of sales	$ 197	$ 424	$ 604	$ 956
Selling, general and administrative	45,438	43,274	156,441	121,013
Research and development	41,513	44,034	120,530	136,753
Restructuring	6,260		6,260
Total operating expenses	93,408	87,732	283,835	258,722
Operating loss	(4,619)	(10,144)	(43,370)	(50,231)
Other income (expense):
Interest expense	(1,802)	(5,237)	(7,423)	(18,579)
Loss on extinguishment of debt		(91,759)		(91,739)
Other income, net	3,661	3,053	10,326	2,691
Total other income (expense), net	1,859	(93,943)	2,903	(107,627)
Loss from continuing operations	(2,760)	(104,087)	(40,467)	(157,858)
(Loss) income from discontinued operations, net of income taxes	(30)	371,540	(320)	400,499
Net (loss) income	$ (2,790)	$ 267,453	$ (40,787)	$ 242,641
Net income (loss) per common and potential common share (basic and diluted):
Net loss from continuing operations, Basic (in dollars per share)	$ (0.07)	$ (3.04)	$ (0.97)	$ (5.05)
Net loss from continuing operations, Diluted (in dollars per share)	(0.07)	(3.04)	(0.97)	(5.05)
Net (loss) income from discontinued operations, Basic (in dollars per share)	0.00	10.83	(0.01)	12.81
Net (loss) income from discontinued operations, Diluted (in dollars per share)	0.00	10.83	(0.01)	12.81
Net (loss) income, Basic (in dollars per share)	(0.07)	7.80	(0.98)	7.76
Net (loss) income, Diluted (in dollars per share)	$ (0.07)	$ 7.80	$ (0.98)	$ 7.76
Weighted average common and potential common shares outstanding:
Basic (in shares)	41,792	34,293	41,731	31,262
Diluted (in shares)	41,792	34,293	41,731	31,262

ICPT Balance Sheet

2023-09-30

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 102,736	$ 50,517
Restricted cash	920	5,343
Investment debt securities, available-for-sale	219,978	435,049
Accounts receivable, net of allowance for credit losses of $65 and $54, respectively	32,479	26,862
Prepaid expenses and other current assets	27,332	22,356
Total current assets	383,445	540,127
Fixed assets, net	822	987
Inventory	2,649	6,462
Security deposits	1,275	1,013
Other assets	4,971	5,122
Total assets	393,162	553,711
Current liabilities:
Accounts payable, accrued expenses and other liabilities	89,494	116,977
Short-term interest payable	1,351	3,531
Current portion of long-term debt		109,569
Total current liabilities	90,845	230,077
Long-term liabilities:
Long-term debt	223,856	223,104
Long-term other liabilities	6,616	7,453
Total liabilities	321,317	460,634
Commitments and contingencies (Note 15)
Stockholders' equity:
Common stock par value $0.001 per share; 90,000,000 shares authorized; 41,811,686 and 41,523,337 shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively	42	42
Additional paid-in capital	2,256,681	2,238,179
Accumulated other comprehensive loss, net	(7,203)	(8,256)
Accumulated deficit	(2,177,675)	(2,136,888)
Total stockholders' equity	71,845	93,077
Total liabilities and stockholders' equity	$ 393,162	$ 553,711

About Intercept Pharmaceuticals Inc

Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults. It is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis and NASH; and other product candidates in various stages of clinical and preclinical development. The company has a license agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. It markets its products through an internal commercial organization and third-party distributors. The company was incorporated in 2002 and is headquartered in Morristown, New Jersey.

CEO	Mr. Jerome B. Durso
WEBSITE	interceptpharma.com
INDUSTRY	Biotechnology
EMPLOYEES	341

Intercept Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for Intercept Pharmaceuticals Inc? What does ICPT stand for in stocks?

ICPT is the stock ticker symbol of Intercept Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Intercept Pharmaceuticals Inc (ICPT)?

As of Tue Nov 14 2023, market cap of Intercept Pharmaceuticals Inc is 794.69 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ICPT stock?

You can check ICPT's fair value in chart for subscribers.

What is the fair value of ICPT stock?

You can check ICPT's fair value in chart for subscribers. The fair value of Intercept Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Intercept Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ICPT so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Intercept Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether ICPT is over valued or under valued. Whether Intercept Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Intercept Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ICPT.

What is Intercept Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Nov 14 2023, ICPT's PE ratio (Price to Earnings) is -12.9 and Price to Sales (PS) ratio is 2.5. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ICPT PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Intercept Pharmaceuticals Inc's stock?

In the past 10 years, Intercept Pharmaceuticals Inc has provided -0.09 (multiply by 100 for percentage) rate of return.